RT Journal Article
SR Electronic
T1 Blueprint for a Pop-up SARS-CoV-2 Testing Lab
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.11.20061424
DO 10.1101/2020.04.11.20061424
A1 Innovative Genomics Institute SARS-CoV-2 Testing Consortium
A1 Hockemeyer, Dirk
A1 Urnov, Fyodor
A1 Green, Ralph
A1 Doudna, Jennifer A.
YR 2020
UL http://medrxiv.org/content/early/2020/04/24/2020.04.11.20061424.abstract
AB The appearance and spread of the novel severe acute respiratory syndrome coronavirus (SARS-CoV-2) led to the official declaration of a global pandemic, with states in the US implementing shelter-in-place orders at an unprecedented scale. SARS-CoV-2 has a robust person-to-person transmission rate and an asymptomatic period of two weeks or more, leading to widespread infection that has overwhelmed healthcare infrastructures around the globe. Effective public health measures require extensive, accurate, and rapid testing to determine infection rates. Here we describe the strategy we used to establish a CLIA-licensed clinical laboratory to perform a validated Laboratory-Developed Test (LDT) for SARS-CoV-2 in Berkeley, California and the surrounding Bay Area community. Our procedures for implementing the technical, regulatory, and data management workstreams necessary for clinical sample processing provide a roadmap to aid others in setting up similar testing centers.Note on Nomenclature in accordance with established virology and infectious disease nomenclature, throughout this document we use “SARS-CoV-2” to refer to the viral agent causing infection and “COVID-19” to refer to the human infectious disease caused by that viral agent.Competing Interest StatementThe authors have declared no competing interest.Funding StatementIGI Founders Fund, Dr. Anders Naar, Rick and Rachel Klausner, and the Shurl and Kay Curci FoundationAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are available in figures, supplemental files and linked materials. https://innovativegenomics.org/sars-cov-2-testing-guide/ Commonly-Used AbbreviationsFDAFood and Drug AdministrationCDCCenters for Disease Control and PreventionCMSCenters for Medicare & Medicaid ServicesCDPHCalifornia Department of Public HealthLFSLaboratory Field Services (division of CDPH that regulates CLIA)LDTLaboratory-Developed TestCLIAClinical Laboratory Improvement AmendmentsEUAEmergency Use Authorization (under FDA)RT-qPCRQuantitative Reverse Transcription Polymerase Chain ReactionLIMSLaboratory Information Management System